Introduction

CBD has moved from niche curiosity to a recognised wellness staple in many parts of daily life. In 2026 the conversation is shifting from oils and balms to more routine categories — notably oral care. This article maps the trend: what’s emerging in CBD toothpaste and mouthwash, why retailers and consumers are paying attention, real market signals and how formulation and regulatory shifts are creating space for CBD to sit alongside toothbrushes and rinses.

What’s trending

• Category convergence — brands are extending CBD into oral formats such as mints, lozenges and experimental rinses that sit naturally in morning and evening routines.
• Microbiome‑friendly formulations — R&D is moving away from alcohol and broad‑spectrum antimicrobials towards enamel‑safe, low‑impact actives that respect oral microbiota.
• Retail momentum — major health & natural retailers and online specialists are expanding CBD assortments, while nimble startups differentiate via organic sourcing, third‑party testing and transparent COAs.
• Sustainability and format innovation — low‑waste options (toothpaste tablets, recyclable glass mouthwash bottles) align with consumer demand for planet‑friendly products.

Why it matters

Several converging data points explain why 2026 could be decisive. First, the UK CBD market reached USD 997.4 million in 2025 and analysts at IMARC Group forecast robust expansion to roughly USD 2.56 billion by 2034. That scale creates capacity for adjacent categories — oral care among them — as brands and retailers chase new shelf space and repeat‑purchase opportunities.

Second, the UK oral care market itself remains substantial: valued at USD 1.89 billion in 2025 and estimated at USD 2.01 billion in 2026, with mouthwash identified as the fastest‑growing oral care segment. That growth is drawing retailer interest in new rinse formats and premium innovations.

Third, consumer preferences have evolved. Market research and analyst commentary show rising demand for natural, alcohol‑free and eco‑friendly oral care — such as toothpaste tablets and low‑waste packaging — which dovetails with CBD’s plant‑based positioning. At the same time, industry commentary in 2026 highlights increasing regulatory clarity and standardisation for CBD products, a positive news hook that is enabling broader retail listings and product launches without the legal ambiguity of earlier years.

Examples: product launches, retailers and formulation moves

We are already seeing practical examples that make mainstream adoption plausible.

• Adjacency through oral formats: Established CBD formats that sit in the mouth are acting as beachheads. Products such as Mr Moxeys Mints Relief and CBD Living Lozenges (Cherry) illustrate how CBD can be presented as a discreet, familiar oral product that consumers are comfortable using alongside brushing and flossing.
• High‑strength tinctures informing formulation: High‑potency oils such as the CBD Living 30ml 4500mg 0% THC tincture demonstrate how manufacturers are confident in delivering consistent, third‑party tested cannabinoid ingredients — a prerequisite for any move into regulated oral care formats.
• Microbiome respect and actives pairing: R&D labs are pairing low‑alcohol or alcohol‑free base formulas with enamel‑safe actives and selective antimicrobial botanicals (e.g. xylitol, green tea polyphenols, zinc citrate). The aim is not to sterilise the mouth but to support freshness and targeted concerns such as sensitivity or breath management while preserving microbial balance — a crucial differentiator for mainstream consumers wary of harsh antiseptics.
• Retail listings and transparency: Major natural health chains and e‑commerce platforms are increasingly open to listing CBD blends that carry robust certificates of analysis, clear ingredient panels and recyclable packaging. That commercial validation accelerates consumer discovery and repeat purchase.

Why manufacturers and retailers are optimistic

Three practical forces underpin optimism: (1) market capacity — the size and growth forecasts of both the CBD and oral care markets create headroom for new SKUs; (2) consumer alignment — sustainability, plant‑based claims and alcohol‑free formulations match evolving shopper values; (3) regulatory improvement — clearer guidance and standards reduce commercial risk for retailers considering shelf space.

Additionally, adjacent CBD topical and personalised pairing trends (CBD plus complementary actives) point to consumer openness to incorporating CBD into daily hygiene rituals. Instead of a single novelty SKU, oral CBD can form part of habitual purchase cycles — the very behaviour retailers prize.

Future outlook — what to watch in 2026 and beyond

• Product formats: Expect toothpaste tablets with microencapsulated CBD, alcohol‑free mouthwashes in recyclable glass, and targeted toothpastes for sensitivity or breath that blend CBD with enamel‑safe actives.
• Labelling & transparency: COAs, clear cannabinoid labelling, and third‑party microbiological testing will become table stakes if brands want mainstream listings.
• Retail expansion: Larger natural‑channel retailers and premium e‑commerce specialists will pilot CBD oral lines, while independent startups will push niche innovation (single‑estate hemp, organic extracts, microbiome‑focused claims).
• Consumer education: Clear, non‑medical messaging explaining what CBD brings to an oral routine (e.g. sensory profiles, plant‑derived positioning, compatibility with low‑alcohol formulas) will drive trial without making health claims.

Risks and guardrails

Broad adoption is not guaranteed. Regulatory shifts must remain predictable, and brands must avoid unsubstantiated health claims. Product safety — particularly with respect to oral mucosal exposure and interactions with existing dental actives — will require robust testing and conservative labelling. Retailers and manufacturers will need to show honesty about what CBD products do and do not do.

Conclusion

Taken together, strong market growth, a fast‑growing mouthwash segment, consumer demand for natural and low‑waste formats, and improved regulatory clarity make 2026 a credible inflection point for CBD oral care in the UK. We are likely to see early mainstream rollouts that favour microbiome‑friendly, alcohol‑free rinses and enamel‑safe pastes — with transparent COAs and sustainable packaging — rather than gimmicky one‑off launches. For consumers and retailers alike, the next 12–24 months will reveal whether CBD can become as familiar in the bathroom cabinet as fluoride and floss.